NCT00934167UnknownPhase 2
NON CLINICAL INFERIORITY OF HEPARIN SODIUM PRODUCED BY HIPOLABOR FARMACEUTICA LTDA COMPARED TO THE HEPARIN SODIUM PRODUCED BY APP PHARMACEUTICALS IN VENOUS THROMBOEMBOLISM PROPHYLAXIS, IN SURGICAL PATIENTS WITH MEDIUM RISK FOR DEVELOPMENT OF THROMBOEMBOLISM.
Conditions
Trial Snapshot
- Phase
- Phase 2
- Sponsor
- Azidus Brasil
- Enrollment
- 140
- Locations
- 2
- Primary Endpoint
- Non-appearance of venous thromboembolism
Study Overview
Brief Summary
The aim of this study is to verify, through clinical examination and doppler, the non-inferiority of the drug test (heparin sodium 5.000UI/0.25 mL - HIPOLABOR) in relation to the drug compared (heparin sodium 5.000USP/mL - APP) in preventing the development of venous thromboembolism (VTE) in patients undergoing surgery for medium risk for the development of this pathology.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Accept all items described in IC signing it in two ways;
- •Be aged between 18 and 60;
- •Be alert to the need for surgery antithrombotic prophylaxis;
- •Be classified as "moderate risk" for developing VTE, according to the protocol of prophylaxis of deep vein thrombosis of the Brazilian Society of Angiology and Vascular Surgery.
Exclusion Criteria
- •Acute coronary syndrome, it will make use of anticoagulation;
- •Immobilization of the lower limbs due to fractures, because in this way will be considered as high risk;
- •History of recent stroke;
- •Patients at high risk of bleeding in which the use of heparin is contra-indicated;
- •General Surgery in patients over 60 years in the case of patients at high risk for VTE;
- •general surgery in patients 40 to 60 years with additional risk factors for development of VTE;
- •Major amputations;
- •More orthopedic surgeries;
- •Patients with pre-surgical diagnosis of malignant neoplasms;
- •Patients with a platelet level below 100x109 / L;
- •Use of anticoagulants 48 hours before randomization;
- •Severe liver failure;
- •Be classified as "Low Risk" or "high risk" for developing VTE, according to Maffei et al. (2005);
- •Pregnancy and lactation.
Outcomes
Primary Outcomes
Non-appearance of venous thromboembolism
Time Frame: 2 h before the start of surgery, 1, 2, 3, 4, 5, 6, 7, 14, 21, 28 days
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 2
Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal FailureChronic Renal FailureNCT00828776Azidus Brasil62
Unknown
Phase 1
PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (SUBCUTANEOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALSHealthyNCT01652638Azidus Brasil44
Unknown
Phase 1
PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (INTRAVENOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALSHealthyNCT01651923Azidus Brasil60
Unknown
Phase 3
Comparison of Two Heparin Formulations in Patients With Chronic Renal Failure.ThrombusNCT00914472Azidus Brasil120
Completed
Not Applicable
Examination of usefulness and safety of heparinoid agent based external medicine (over counter drug) for facial dryness symptom.JPRN-UMIN000018986Osaka city university graduate school of medicine, department of dermatology50